Neurogene (NGNE) Competitors

Neurogene logo
$23.10 -0.20 (-0.86%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$22.88 -0.22 (-0.95%)
As of 07:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NGNE vs. MAZE, VCYT, BCRX, COAG, and RXRX

Should you buy Neurogene stock or one of its competitors? Neurogene's main competitors and comparable companies include Maze Therapeutics (MAZE), Veracyte (VCYT), BioCryst Pharmaceuticals (BCRX), Hemab Therapeutics (COAG), and Recursion Pharmaceuticals (RXRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Neurogene compare to Maze Therapeutics?

Maze Therapeutics (NASDAQ:MAZE) and Neurogene (NASDAQ:NGNE) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

Maze Therapeutics' return on equity of -38.39% beat Neurogene's return on equity.

Company Net Margins Return on Equity Return on Assets
Maze TherapeuticsN/A -38.39% -32.57%
Neurogene N/A -44.36%-40.61%

Maze Therapeutics presently has a consensus price target of $65.50, suggesting a potential upside of 99.27%. Neurogene has a consensus price target of $79.57, suggesting a potential upside of 244.47%. Given Neurogene's higher probable upside, analysts plainly believe Neurogene is more favorable than Maze Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Maze Therapeutics
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
3 Strong Buy rating(s)
3.08
Neurogene
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
3.00

Maze Therapeutics has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market. Comparatively, Neurogene has a beta of 1.75, meaning that its stock price is 75% more volatile than the broader market.

In the previous week, Maze Therapeutics had 4 more articles in the media than Neurogene. MarketBeat recorded 17 mentions for Maze Therapeutics and 13 mentions for Neurogene. Neurogene's average media sentiment score of 0.67 beat Maze Therapeutics' score of -0.39 indicating that Neurogene is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Maze Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Neurogene
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Neurogene has lower revenue, but higher earnings than Maze Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Maze Therapeutics$167.50M10.73-$131.12M-$2.65N/A
Neurogene$930K514.16-$90.35M-$5.09N/A

52.4% of Neurogene shares are owned by institutional investors. 5.3% of Maze Therapeutics shares are owned by insiders. Comparatively, 11.7% of Neurogene shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Maze Therapeutics beats Neurogene on 9 of the 15 factors compared between the two stocks.

How does Neurogene compare to Veracyte?

Veracyte (NASDAQ:VCYT) and Neurogene (NASDAQ:NGNE) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends.

In the previous week, Neurogene had 5 more articles in the media than Veracyte. MarketBeat recorded 13 mentions for Neurogene and 8 mentions for Veracyte. Neurogene's average media sentiment score of 0.67 beat Veracyte's score of 0.12 indicating that Neurogene is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Veracyte
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Neurogene
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Veracyte has a net margin of 21.80% compared to Neurogene's net margin of 0.00%. Veracyte's return on equity of 8.99% beat Neurogene's return on equity.

Company Net Margins Return on Equity Return on Assets
Veracyte21.80% 8.99% 8.34%
Neurogene N/A -44.36%-40.61%

Veracyte presently has a consensus target price of $44.50, suggesting a potential upside of 83.66%. Neurogene has a consensus target price of $79.57, suggesting a potential upside of 244.47%. Given Neurogene's stronger consensus rating and higher possible upside, analysts clearly believe Neurogene is more favorable than Veracyte.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Veracyte
1 Sell rating(s)
5 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.42
Neurogene
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
3.00

Veracyte has higher revenue and earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veracyte$517.15M3.78$66.35M$1.5515.63
Neurogene$930K514.16-$90.35M-$5.09N/A

52.4% of Neurogene shares are held by institutional investors. 1.6% of Veracyte shares are held by company insiders. Comparatively, 11.7% of Neurogene shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Veracyte has a beta of 1.98, suggesting that its stock price is 98% more volatile than the broader market. Comparatively, Neurogene has a beta of 1.75, suggesting that its stock price is 75% more volatile than the broader market.

Summary

Veracyte and Neurogene tied by winning 8 of the 16 factors compared between the two stocks.

How does Neurogene compare to BioCryst Pharmaceuticals?

Neurogene (NASDAQ:NGNE) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

In the previous week, Neurogene had 11 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 13 mentions for Neurogene and 2 mentions for BioCryst Pharmaceuticals. Neurogene's average media sentiment score of 0.67 beat BioCryst Pharmaceuticals' score of 0.56 indicating that Neurogene is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Neurogene
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
BioCryst Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Neurogene has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market.

BioCryst Pharmaceuticals has higher revenue and earnings than Neurogene. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neurogene$930K514.16-$90.35M-$5.09N/A
BioCryst Pharmaceuticals$874.84M2.21$263.86M-$1.42N/A

Neurogene presently has a consensus price target of $79.57, indicating a potential upside of 244.47%. BioCryst Pharmaceuticals has a consensus price target of $20.38, indicating a potential upside of 171.67%. Given Neurogene's stronger consensus rating and higher possible upside, equities research analysts clearly believe Neurogene is more favorable than BioCryst Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neurogene
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
3.00
BioCryst Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.56

Neurogene has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -37.40%. Neurogene's return on equity of -44.36% beat BioCryst Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
NeurogeneN/A -44.36% -40.61%
BioCryst Pharmaceuticals -37.40%-92.91%66.56%

52.4% of Neurogene shares are owned by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 11.7% of Neurogene shares are owned by company insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Neurogene beats BioCryst Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Neurogene compare to Hemab Therapeutics?

Hemab Therapeutics (NASDAQ:COAG) and Neurogene (NASDAQ:NGNE) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations, dividends and media sentiment.

Hemab Therapeutics' return on equity of 0.00% beat Neurogene's return on equity.

Company Net Margins Return on Equity Return on Assets
Hemab TherapeuticsN/A N/A N/A
Neurogene N/A -44.36%-40.61%

Hemab Therapeutics currently has a consensus price target of $56.00, indicating a potential upside of 43.37%. Neurogene has a consensus price target of $79.57, indicating a potential upside of 244.47%. Given Neurogene's stronger consensus rating and higher possible upside, analysts plainly believe Neurogene is more favorable than Hemab Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hemab Therapeutics
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.70
Neurogene
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
3.00

In the previous week, Neurogene had 11 more articles in the media than Hemab Therapeutics. MarketBeat recorded 13 mentions for Neurogene and 2 mentions for Hemab Therapeutics. Neurogene's average media sentiment score of 0.67 beat Hemab Therapeutics' score of -0.03 indicating that Neurogene is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Hemab Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Neurogene
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

52.4% of Neurogene shares are owned by institutional investors. 11.7% of Neurogene shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Hemab Therapeutics has higher earnings, but lower revenue than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hemab TherapeuticsN/AN/AN/A-$24.78N/A
Neurogene$930K514.16-$90.35M-$5.09N/A

Summary

Neurogene beats Hemab Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Neurogene compare to Recursion Pharmaceuticals?

Neurogene (NASDAQ:NGNE) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

Neurogene has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market.

In the previous week, Neurogene had 1 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 13 mentions for Neurogene and 12 mentions for Recursion Pharmaceuticals. Neurogene's average media sentiment score of 0.67 beat Recursion Pharmaceuticals' score of 0.07 indicating that Neurogene is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Neurogene
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Recursion Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Neutral

52.4% of Neurogene shares are owned by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 11.7% of Neurogene shares are owned by company insiders. Comparatively, 6.7% of Recursion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Neurogene has higher earnings, but lower revenue than Recursion Pharmaceuticals. Neurogene is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neurogene$930K514.16-$90.35M-$5.09N/A
Recursion Pharmaceuticals$74.68M22.68-$644.76M-$0.90N/A

Neurogene has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -697.15%. Neurogene's return on equity of -44.36% beat Recursion Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
NeurogeneN/A -44.36% -40.61%
Recursion Pharmaceuticals -697.15%-47.85%-36.26%

Neurogene presently has a consensus price target of $79.57, suggesting a potential upside of 244.47%. Recursion Pharmaceuticals has a consensus price target of $7.58, suggesting a potential upside of 178.68%. Given Neurogene's stronger consensus rating and higher probable upside, equities analysts plainly believe Neurogene is more favorable than Recursion Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neurogene
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
3.00
Recursion Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20

Summary

Neurogene beats Recursion Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

Get Neurogene News Delivered to You Automatically

Sign up to receive the latest news and ratings for NGNE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NGNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NGNE vs. The Competition

MetricNeurogeneBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$482.33M$4.06B$7.83B$11.74B
Dividend YieldN/A3.63%2.47%4.47%
P/E RatioN/A26.6634.2628.24
Price / Sales514.1615.788.485.70
Price / CashN/A22.9521.0121.90
Price / Book1.354.184.463.72
Net Income-$90.35M-$24.15M$3.52B$393.10M
7 Day Performance-7.97%-7.78%-5.92%-5.76%
1 Month Performance-0.65%-5.96%-4.58%-7.14%
1 Year Performance8.15%-8.08%-1.93%-7.46%

Neurogene Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NGNE
Neurogene
2.3433 of 5 stars
$23.10
-0.9%
$79.57
+244.5%
+2.8%$482.33M$930KN/A131
MAZE
Maze Therapeutics
2.6414 of 5 stars
$35.22
+0.9%
$64.55
+83.3%
-2.0%$1.96B$167.50MN/A141
VCYT
Veracyte
3.2411 of 5 stars
$24.19
-6.7%
$46.00
+90.2%
-38.3%$1.95B$517.15M15.68755
BCRX
BioCryst Pharmaceuticals
2.5297 of 5 stars
$7.52
-1.5%
$20.38
+171.1%
+6.7%$1.92B$874.84MN/A435
COAG
Hemab Therapeutics
2.4116 of 5 stars
$40.53
-5.3%
$56.00
+38.2%
N/A$1.89BN/AN/A59

Related Companies and Tools


This page (NASDAQ:NGNE) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners